This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carson, D. A. Articles by Wasson, D. B. Search for Related Content PubMed PubMed Citation Articles by Carson, D. A. Articles by Wasson, D. B.

Characterization of an Adenosine 5'-Triphosphate- and Deoxyadenosine 5'-Triphosphate-activated Nucleotidase from Human Malignant Lymphocytes¹

Department of Clinical Research, Scripps Clinic and Research Foundation, La Jolla, California 92037

The kinetic properties of a soluble, magnesium-dependent 5'-nucleotidase from human malignant lymphocytes have been determined. The partially purified enzyme is distinct from plasma membrane-associated 5'-nucleotidase and is free of nonspecific phosphatase activity. Among purine ribonucleotides, it reacted efficiently with inosine 5'-monophosphate and guanosine 5'-monophosphate and to a lesser degree with deoxyguanosine 5'-monophosphate. Adenosine 5'-monophosphate and deoxyadenosine 5'-monophosphate were 30-fold less efficient substrates. Increasing concentrations of adenosine 5'-triphosphate and deoxyadenosine 5'-triphosphate from 0 to 3 mM enhanced 5'-nucleotidase activity up to 7-fold. Guanosine 5'-triphosphate and deoxyguanosine 5'-triphosphate were much less effective enzyme activators, while uridine 5'-triphosphate was without effect. Inorganic phosphate inhibited dephosphorylating activity in both adenosine 5'-triphosphate-supplemented and unsupplemented buffer. The activation of this 5'-nucleotidase by deoxyadenosine 5'-triphosphate, combined with the relative inability of the enzyme to dephosphorylate deoxyadenosine 5'-monophosphate, conceivably may contribute to the adenine nucleotide degradation induced by deoxyadenosine in normal and malignant lymphocytes.

¹ Supported by Grants GM 23200 and CA 31497 from the USPHS.

Received 4/26/82. Accepted 7/21/82.

This article has been cited by other articles:

				P. J. O'DWYER, B. WAGNER, B. LEYLAND-JONES, R. E. WITTES, B. D. CHESON, and D. F. HOTH 2'-Deoxycoformycin (Pentostatin) for Lymphoid Malignancies: Rational Development of an Active New Drug Ann Intern Med, May 1, 1988; 108(5): 733 - 743. [Abstract] [PDF]